Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
The Pharma Data
JULY 8, 2021
When added to the EMPEROR-Reduced trial results, these findings demonstrate Jardiance’s efficacy in all forms of heart failure regardless of ejection fraction. ” The EMPEROR-Preserved trial investigated Jardiance 10 mg compared with placebo. vice president, Product Development, Lilly.
52 
Let's personalize your content